ReviewCureus2026
Current Concepts in Platelet-Rich Plasma Therapy for Lateral Epicondylitis Through a Histopathological and Clinical Lens.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lateral epicondylitis (LE), or tennis elbow, is a degenerative tendinopathy of the extensor carpi radialis brevis (ECRB) tendon. While most patients improve with conservative therapies, a subset experience chronic, refractory symptoms requiring advanced interventions. Platelet-rich plasma (PRP) has emerged as a promising biologic treatment, offering an autologous source of growth factors that may enhance tendon healing. This review examines current concepts in PRP therapy for LE, including basic science mechanisms, animal studies, and clinical outcomes. Chronic LE is characterized by a paucity of inflammatory infiltrate and increased programmed cell death (PCD), suggesting a limited intrinsic healing response. PRP delivers key growth factors (vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), fibroblast growth factor (FGF), and transforming growth factor-beta (TGF-β)), each of which has demonstrated pro-healing properties in animal models by promoting angiogenesis, fibroblast proliferation, and collagen remodeling. Clinical data on PRP are heterogeneous, with some randomized trials and long-term follow-up studies demonstrating significant improvement in pain and function, while others show minimal benefit. Comparisons with corticosteroids suggest that PRP may offer superior long-term outcomes, although corticosteroids provide better short-term relief. PRP has also shown comparable efficacy to surgical debridement, offering a less invasive alternative. The role of leukocyte concentration in PRP remains unresolved; while leukocyte-poor PRP may reduce fibrosis and inflammation, clinical studies have not definitively favored one formulation over another. Overall, PRP therapy represents a biologically plausible, relatively safe, and potentially effective treatment option for refractory LE. Further research is needed to optimize formulation, delivery, and patient selection to fully realize its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.